SCHEMBL10089394

SCHEMBL10089394

CCc1cccc(Oc2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 4/20 0.51
HTT P42858 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
BCL2 P10415 1/20 0.49
FFAR4 Q5NUL3 3/20 0.48
FFAR1 O14842 2/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LTA4H P09960 2/20 0.47
PTGES O14684 1/20 0.47
ALOX5 P09917 1/20 0.47
GSTP1 P09211 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PTGS2 P35354 1/20 0.44
HPGD P15428 1/20 0.44
CETP P11597 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407250 0.91 KDM4E (0.58) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL10089395 0.88 BCL2 (0.50) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL11736722 0.85 ALDH1A1 (0.53) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL9488681 0.85 ALDH1A1 (0.50) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL30358275 0.85 ALDH1A1 (0.50) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL8333210 0.83 TP53 (0.52) TSHRLTA4H
SCHEMBL13437634 0.83 LTA4H (0.55) FFAR1TSHRLTA4HGSTP1
SCHEMBL20976189 0.83 LTA4H (0.55) FFAR1TSHRLTA4HGSTP1
SCHEMBL11169763 0.83 FFAR1 (0.48) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL8243884 0.82 FFAR1 (0.51) ALDH1A1KDM4EHTTTDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-12 US disclosed
US-8003693-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-08-23 US disclosed
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-19 US disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis FAAH, FAAH2, CNR2 ALDH1A1 681/4885KDM4E 919/4885HTT 2848/4885
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS FAAH, FAAH2, CNR2 ALDH1A1 734/4885KDM4E 938/4885HTT 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.